Literature DB >> 29110035

[New aspects on giant cell tumor of bone].

J Lüke1, M Hasenfratz1, P Möller1, T F E Barth2.   

Abstract

A giant cell tumor of bone (GCTB) is one of the giant cell-rich lesions of bone and has to be differentiated from non-ossifying fibroma, aneurysmatic bone cyst, chondroblastoma, "brown tumor" and osteosarcoma containing giant cells. A hallmark of GCTB is the presence of the distinct histone 3 (H3F3A) mutation G34W and its detection either by sequencing methods or using immunohistochemistry with a novel antibody against this mutational site. Worrisome is the fact that under denosumab therapy a histological change of the lesions can be seen and there are first reports of sarcomas arising after therapy. When diagnosing giant cell-rich lesions, pathologists should be aware of the various differential diagnoses and morphological spectrum within GCTB.

Entities:  

Keywords:  Denosumab; Differential diagnosis; Giant cell rich lesions; H3F3A mutation; Histone 3

Mesh:

Substances:

Year:  2018        PMID: 29110035     DOI: 10.1007/s00292-017-0391-9

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  30 in total

1.  P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.

Authors:  Tina Shooshtarizadeh; Mandana Rahimi; Sajjadeh Movahedinia
Journal:  Pathol Res Pract       Date:  2016-07-14       Impact factor: 3.250

2.  Surgical management for giant cell tumor of bones.

Authors:  El Sayed Ashraf Khalil; Alaa Younis; Sherif A Aziz; Magdy El Shahawy
Journal:  J Egypt Natl Canc Inst       Date:  2004-09

3.  Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.

Authors:  Daniel G Branstetter; Scott D Nelson; J Carlos Manivel; Jean-Yves Blay; Sant Chawla; David M Thomas; Susie Jun; Ira Jacobs
Journal:  Clin Cancer Res       Date:  2012-06-18       Impact factor: 12.531

4.  Histologic Spectrum of Giant Cell Tumor (GCT) of Bone in Patients 18 Years of Age and Below: A Study of 63 Patients.

Authors:  Alyaa Al-Ibraheemi; Carrie Y Inwards; Riyam T Zreik; Doris E Wenger; Sarah M Jenkins; Jodi M Carter; Jennifer M Boland; Peter S Rose; Long Jin; Andre M Oliveira; Karen J Fritchie
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

5.  Multicentric giant cell tumor of bone.

Authors:  C A Cummins; M T Scarborough; W F Enneking
Journal:  Clin Orthop Relat Res       Date:  1996-01       Impact factor: 4.176

6.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.

Authors:  Sam Behjati; Patrick S Tarpey; Nadège Presneau; Susanne Scheipl; Nischalan Pillay; Peter Van Loo; David C Wedge; Susanna L Cooke; Gunes Gundem; Helen Davies; Serena Nik-Zainal; Sancha Martin; Stuart McLaren; Victoria Goodie; Ben Robinson; Adam Butler; Jon W Teague; Dina Halai; Bhavisha Khatri; Ola Myklebost; Daniel Baumhoer; Gernot Jundt; Rifat Hamoudi; Roberto Tirabosco; M Fernanda Amary; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Adrienne M Flanagan
Journal:  Nat Genet       Date:  2013-10-27       Impact factor: 38.330

Review 7.  Pulmonary metastasis of giant cell tumor of bones.

Authors:  Aikeremujiang Muheremu; Xiaohui Niu
Journal:  World J Surg Oncol       Date:  2014-08-20       Impact factor: 2.754

8.  Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics.

Authors:  Nadège Presneau; Daniel Baumhoer; Sam Behjati; Nischalan Pillay; Patrick Tarpey; Peter J Campbell; Gernot Jundt; Rifat Hamoudi; David C Wedge; Peter Van Loo; A Bassim Hassan; Bhavisha Khatri; Hongtao Ye; Roberto Tirabosco; M Fernanda Amary; Adrienne M Flanagan
Journal:  J Pathol Clin Res       Date:  2015-03-16

9.  H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.

Authors:  Fernanda Amary; Fitim Berisha; Hongtao Ye; Manu Gupta; Alice Gutteridge; Daniel Baumhoer; Rebecca Gibbons; Roberto Tirabosco; Paul O'Donnell; Adrienne M Flanagan
Journal:  Am J Surg Pathol       Date:  2017-08       Impact factor: 6.394

View more
  1 in total

1.  [H3F3A mutated multicentric giant cell tumor of bone : A very rare primary bone disease].

Authors:  J P Giesche; A von Baer; T Breining; R Marienfeld; K Mellert; J Lüke; M Schultheiss; P Möller; T F E Barth
Journal:  Pathologe       Date:  2018-09       Impact factor: 1.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.